Abstract: A system and/or method that can reduce impact of network latency can be provided. Information associated with a user device participating in an online meeting can be determined, for user devices connecting to the online meeting. Based on the information, the user devices can be grouped. For each of the user devices in a group, network quality associated with network connection between a user device in the group and a server managing the online meeting can be evaluated. Based on the network quality, at least one user device in the group can be designated to operate as a sharer device to at least one other user device in the group. The sharer device can be caused to stream data directly from the server during the online meeting. That one other user device can be caused to connect with and stream data from the sharer device.

Abstract: The invention provides a method for continuously producing composite nanoparticles, the method comprising heating a precursor mixture with supercritical water, wherein the mixture contains a first compound capable of transitioning from a monoclinic to a tetragonal rutile crystal state; cooling the heated mixture to obtain core particles of a predetermined shape and size; encapsulating the core particle with a second precursor to create a core-shell construct; and encapsulating the construct with an organic material. Also provided is a device for continuously synthesizing composite nanoparticles, the device comprising a water supply and a precursor supply; a means for heating the water, a continuous flow hydrothermal reaction chamber adapted to receive the heated water and precursor, a means for chilling the heated water and precursor, and a capping agent supply positioned downstream of the reaction chamber.

Abstract: The present disclosure relates to: a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof; and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.

Abstract: The present disclosure relates to: a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof; and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.

Abstract: The present disclosure relates to: a) crystalline forms of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof; and methods of producing essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.

Abstract: The present disclosure relates to: a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, h) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof; and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.

Abstract: The present disclosure relates to: a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof; and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.

Abstract: The present disclosure relates to a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof, and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.

Abstract: There is provided a recombinant bacterium comprising at least one overexpressed acyl-ACP thioesterase gene, and wherein at least one gene from the tricarboxylic acid cycle or glycolysis or both is inactivated. There is also provided a method for producing fatty acids, said method comprising culturing bacteria comprising at least one overexpressed acyl-ACP thioesterase gene in a growth medium in a container having walls; allowing said bacteria to secrete fatty acids; and collecting said fatty acids. Acid supplementation is also shown to increase productivity.

Abstract: A system for monitoring physiological condition includes a device for collecting readings and a monitoring device. The collecting device includes a number of collecting units configured to be selected human body. Based on different requirements, different numbers of collecting units can be selected to be attached to different portions of the living subject to collect readings. The selected collecting units transmit the readings to the monitoring device via wireless communication networks. The monitoring device can analyze the readings and generate a report.

Abstract: A device for measuring blood measure measures variations in electrical charges on the body as a result of heart activity. A method using the same is also described. The method acquires ECG signal collected by a collection unit of the device for measuring blood measure, processes the ECG signal, extracts feature from the ECG signal, and computes blood pressure according to the feature extracted from the ECG signal.

Abstract: The present invention discloses a process for increasing the production of free fatty acids at high yield (close to maximum theoretical yield), with various fatty acid compositions and various percentage of fatty acids accumulated intracellularly. This invention will enable the efficient production of other products derived from free fatty acids and/or products that can be branched out from the fatty acid synthesis pathways.

Abstract: A wearable electronic device includes a signal capturing assembly and a holder. The holder includes a case defining a receiving slot configured for receiving the signal capturing assembly, a first connecting electrode, and a second connecting electrode. The first and second connecting electrodes protrude from a bottom surface of the case and are electronically connected to the signal capturing assembly. The first and second connecting electrodes detect vital signs of a user and transmit the detected vital signs to the signal capturing assembly.

Abstract: A wearable electronic device includes a signal capturing assembly and a wearable assembly. The signal capturing assembly is configured for detecting and processing vital signs from a user and defines at least one port. The signal capturing assembly includes a base, a first cover, a second cover, a third cover, a first electrode, and a core module. The first, second, third covers cover the base to form a receiving chamber to accommodate the core module. The first electrode is extended through the base and electronically connected to the core module The wearable assembly is detachably connected to the signal capturing assembly through the at least one port.

Abstract: There is provided a recombinant bacterium comprising at least one overexpressed acyl-ACP thioesterase gene, and wherein at least one gene from the tricarboxylic acid cycle or glycolysis or both is inactivated. There is also provided a method for producing fatty acids, said method comprising culturing bacteria comprising at least one overexpressed acyl-ACP thioesterase gene in a growth medium in a container having walls; allowing said bacteria to secrete fatty acids; and collecting said fatty acids. Acid supplementation is also shown to increase productivity.

Abstract: There is provided a recombinant bacterium comprising at least one overexpressed acyl-ACP thioesterase gene, and wherein at least one gene from the tricarboxylic acid cycle or glycolysis or both is inactivated. There is also provided a method for producing fatty acids, said method comprising culturing bacteria comprising at least one overexpressed acyl-ACP thioesterase gene in a growth medium in a container having walls; allowing said bacteria to secrete fatty acids; and collecting said fatty acids. Acid supplementation is also shown to increase productivity.

Abstract: A wearable electronic device includes a signal capturing assembly and a wearable assembly. The signal capturing assembly is configured for detecting and processing vital signs from a user and defines at least one port. The signal capturing assembly includes a base, a first cover, a second cover, a third cover, a first electrode, and a core module. The first, second, third covers cover the base to form a receiving chamber to accommodate the core module. The first electrode is extended through the base and electronically connected to the core module The wearable assembly is detachably connected to the signal capturing assembly through the at least one port.

Abstract: A wearable electronic device includes a signal capturing assembly and a holder. The holder includes a case defining a receiving slot configured for receiving the signal capturing assembly, a first connecting electrode, and a second connecting electrode. The first and second connecting electrodes protrude from a bottom surface of the case and are electronically connected to the signal capturing assembly. The first and second connecting electrodes detect vital signs of a user and transmit the detected vital signs to the signal capturing assembly.

Abstract: Methods of improving fatty acid production in bacteria, yeast, algae, and various other microbes are presented, by either supplementing the medium with millimolar amounts of magnesium, by overexpressing a magnesium transporter, or both.

Abstract: The present invention provides a host microorganism with a deletion, disruption or mutation in one or more enzymes of a glycerol dissimilation pathway and a plasmid without an antibiotic resistance gene but carrying one or more genes encoding enzymes involved in glycerol dissimilation, wherein the plasmid is stably maintained by the host microorganism when cultured on glycerol as a carbon source. Such a plasmid maintenance system is beneficial in applications where the presence of an antibiotic resistance gene or the use of antibiotics is either prohibited or problem.